The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells

Current Medicinal Chemistry

Volumn 19, Issue 12, 2012, Pages 1780-1791

  Rosental, B ^a   Appel, M Y ^a   Yossef, R ^a   Hadad, U ^a   Brusilovsky, M ^a   Porgador, A ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Cancer; Chemotherapy; Ligands; Natural cytotoxicity receptors (NCRs); Natural killer (NK) cells; Radiotherapy; Receptors

Indexed keywords

ALPHA INTERFERON; BELINOSTAT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BLEOMYCIN; BORTEZOMIB; BUTYRIC ACID; CISPLATIN; DASATINIB; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOTEMUSTINE; GAMMA INTERFERON; GEMCITABINE; HLA ANTIGEN CLASS 1; IMATINIB; LIGAND; MELPHALAN; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; NILOTINIB; RETINOIC ACID; ROMIDEPSIN; SORAFENIB; TRICHOSTATIN A; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL FUNCTION; CELL STRESS; CYTOTOXICITY; GAMMA IRRADIATION; GLIOMA; HUMAN; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; RADIATION, IONIZING; RECEPTORS, NATURAL KILLER CELL;

EID: 84860520974     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800099730     Document Type: Article

References (150)

1. Lake, R. A.; Robinson, B. W. S. Immunotherapy and chemotherapy-a practical partnership. Nature Reviews Cancer, 2005, 5, 397-405.
2. Van der Most, R.; Currie, A.; Robinson, B.; Lake, R. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death & Differentiation, 2007, 15, 13-20. (Pubitemid 350286168)
3. Lodoen, M. B.; Lanier, L. L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol., 2006, 18, 391-398. (Pubitemid 43947576)
4. Imai, K.; Matsuyama, S.; Miyake, S.; Suga, K.; Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. The Lancet, 2000, 356, 1795-1799.
5. Kelly, J. M.; Darcy, P. K.; Markby, J. L.; Godfrey, D. I.; Takeda, K.; Yagita, H.; Smyth, M. J. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol., 2001, 3, 83-90.
6. Diefenbach, A.; Jensen, E. R.; Jamieson, A. M.; Raulet, D. H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. J. Neurophysiol., 1996, 76, 2790-2793.
7. López-Botet, M.; Angulo, A.; Guma, M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens, 2004, 63, 195-203. (Pubitemid 38297253)
8. Colonna, M.; Jonjic, S.; Watzl, C. Natural killer cells: fighting viruses and much more. Nat. Immunol., 2011, 12, 107-110.
9. Campbell, K. S.; Purdy, A. K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 2011, 132, 315-25.
10. Moretta, L.; Moretta, A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J., 2003, 23, 255-259.
11. Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. Nat. Immunol., 2008, 9, 503-510. (Pubitemid 351560519)
12. Moretta, A.; Bottino, C.; Vitale, M.; Pende, D.; Cantoni, C.; Mingari, M. C.; Biassoni, R.; Moretta, L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol., 2001, 19, 197-223. (Pubitemid 32368034)
13. Arnon, T. I.; Lev, M.; Katz, G.; Chernobrov, Y.; Porgador, A.; Mandelboim, O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol., 2001, 31, 2680-2689. (Pubitemid 32898735)
14. Ho, J. W.; Hershkovitz, O.; Peiris, M.; Zilka, A.; Bar-Ilan, A.; Nal, B.; Chu, K.; Kudelko, M.; Kam, Y. W.; Achdout, H.; Mandelboim, M.; Altmeyer, R.; Mandelboim, O.; Bruzzone, R.; Porgador, A. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J. Virol., 2008, 82, 2028.
15. Arnon, T. I.; Achdout, H.; Levi, O.; Markel, G.; Saleh, N.; Katz, G.; Gazit, R.; Gonen-Gross, T.; Hanna, J.; Nahari, E.; Porgador, A.; Honigman, A.; Plachter, B.; Mevorach, D.; Wolf, D. G.; Mandelboim, O. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol., 2005, 6, 515-523. (Pubitemid 41716765)
16. Hershkovitz, O.; Rosental, B.; Rosenberg, L. A.; Navarro-Sanchez, M. E.; Jivov, S.; Zilka, A.; Gershoni-Yahalom, O.; Brient-Litzler, E.; Bedouelle, H.; Ho, J. W.; Campbell, K. S.; Rager-Zisman, B.; Despres, P.; Porgador, A. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. The Journal of Immunology, 2009, 183, 2610.
17. Mandelboim, O.; Porgador, A. NKp46. Int. J. Biochem. Cell Biol., 2001, 33, 1147-1150.
18. Bloushtain, N.; Qimron, U.; Bar-Ilan, A.; Hershkovitz, O.; Gazit, R.; Fima, E.; Korc, M.; Vlodavsky, I.; Bovin, N. V.; Porgador, A. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. The Journal of Immunology, 2004, 173, 2392.
19. Garg, A.; Barnes, P. F.; Porgador, A.; Roy, S.; Wu, S.; Nanda, J. S.; Griffith, D. E.; Girard, W. M.; Rawal, N.; Shetty, S.; Vankayalapati, R. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. The Journal of Immunology, 2006, 177, 6192.
20. Pogge von Strandmann, E.; Simhadri, V. R.; von Tresckow, B.; Sasse, S.; Reiners, K. S.; Hansen, H. P.; Rothe, A.; Böll, B.; Simhadri, V. L.; Borchmann, P.; McKinnon, P. J.; Hallek, M.; Engert, A. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity, 2007, 27, 965-974. (Pubitemid 350251218)
21. Brandt, C. S.; Baratin, M.; Yi, E. C.; Kennedy, J.; Gao, Z.; Fox, B.; Haldeman, B.; Ostrander, C. D.; Kaifu, T.; Chabannon, C.; Moretta, A.; West, R.; Xu, W.; Vivier, E.; Levin, S. D. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med., 2009, 206, 1495.
22. Garrido, F.; Cabrera, T.; Lopez-Nevot, M. A.; Ruiz-Cabello, F. HLA class I antigens in human tumors. Adv. Cancer Res., 1995, 67, 155-195.
23. Ljunggren, H.; Kärre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today, 1990, 11, 237-244. (Pubitemid 20198988)
24. Sanchez, C.; Le Treut, T.; Boehrer, A.; Knoblauch, B.; Imbert, J.; Olive, D.; Costello, R. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunology, Immunotherapy, 2010, 1-13.
25. Hoppe, R. Hodgkin's disease: complications of therapy and excess mortality. Annals of oncology, 1997, 8, S115.
26. Stokes, M. E.; Muehlenbein, C. E.; Marciniak, M. D.; Faries, D. E.; Motabar, S.; Gillespie, T. W.; Lipscomb, J.; Knopf, K. B.; Buesching, D. P. Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer. 648 Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications, 2009, 15, 669-682.
27. Park, S.; Kim, H.; Kim, C.; Choi, I.; Lee, J.; Lee, J.; Ryu, K.; Kim, Y.; Bae, J.; Kim, N. Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br. J. Cancer, 2008, 98, 1305-1311. (Pubitemid 351543578)
28. Wang, J.; Fan, Y.; Xu, B. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother. Pharmacol., 2010, 66, 597-603.
29. Trinchieri, G. Biology of natural killer cells. Adv. Immunol., 1989, 47, 187-376. (Pubitemid 20010960)
30. Vivier, E.; Nunès, J. A.; Vély, F. Natural killer cell signaling pathways. Science, 2004, 306, 1517.
31. Zilka, A.; Landau, G.; Hershkovitz, O.; Bloushtain, N.; Bar-Ilan, A.; Benchetrit, F.; Fima, E.; Van Kuppevelt, T. H.; Gallagher, J. T.; Elgavish, S.; Porgador, A. Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry (N. Y.), 2005, 44, 14477-14485. (Pubitemid 41567456)
32. Hershkovitz, O.; Jivov, S.; Bloushtain, N.; Zilka, A.; Landau, G.; Bar-Ilan, A.; Lichtenstein, R. G.; Campbell, K. S.; van Kuppevelt, T. H.; Porgador, A. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry (N. Y.), 2007, 46, 7426-7436. (Pubitemid 46986369)
33. Hecht, M. L.; Rosental, B.; Horlacher, T.; Hershkovitz, O.; De Paz, J. L.; Noti, C.; Schauer, S.; Porgador, A.; Seeberger, P. H. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. Journal of proteome research, 2009, 8, 712-720.
34. Bauer, S.; Groh, V.; Wu, J.; Steinle, A.; Phillips, J. H.; Lanier, L. L.; Spies, T. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science, 1999, 285, 727.
35. Cosman, D.; Müllberg, J.; Sutherland, C. L.; Chin, W.; Armitage, R.; Fanslow, W.; Kubin, M.; Chalupny, N. J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 2001, 14, 123-133. (Pubitemid 32206515)
36. Conejo-Garcia, J. R.; Benencia, F.; Courreges, M. C.; Khang, E.; Zhang, L.; Mohamed-Hadley, A.; Vinocur, J. M.; Buckanovich, R. J.; Thompson, C. B.; Levine, B.; Coukos, G. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer. Biol. Ther., 2003, 2, 446-451.
37. Lanier, L. L.; Corliss, B.; Wu, J.; Phillips, J. H. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity, 1998, 8, 693-701. (Pubitemid 28294516)
38. Kaiser, B. K.; Barahmand-pour, F.; Paulsene, W.; Medley, S.; Geraghty, D. E.; Strong, R. K. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. The Journal of Immunology, 2005, 174, 2878.
39. Parham, P. MHC class I molecules and KIRs in human history, health and survival. Nature Reviews Immunology, 2005, 5, 201-214. (Pubitemid 40364822)
40. Lanier, L. L. NK cell recognition. Annu. Rev. Immunol., 2005, 23, 225-274. (Pubitemid 40563170)
41. Zitvogel, L.; Kepp, O.; Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol., 2011, 8, 151-160.
42. Armeanu, S.; Krusch, M.; Baltz, K. M.; Weiss, T. S.; Smirnow, I.; Steinle, A.; Lauer, U. M.; Bitzer, M.; Salih, H. R. Direct and natural killer cellmediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clinical Cancer Research, 2008, 14, 3520.
43. Soriani, A.; Zingoni, A.; Cerboni, C.; Iannitto, M. L.; Ricciardi, M. R.; Di Gialleonardo, V.; Cippitelli, M.; Fionda, C.; Petrucci, M. T.; Guarini, A. Foa, R.; Santoni, A. ATM-ATR. dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 2009, 113, 3503.
44. Butler, J. E.; Moore, M. B.; Presnell, S. R.; Chan, H. W.; Chalupny, N. J.; Lutz, C. T. Proteasome regulation of ULBP1 transcription. The Journal of Immunology, 2009, 182, 6600.
45. Skov, S.; Pedersen, M. T.; Andresen, L.; Thor Straten, P.; Woetmann, A.; Odum, N. Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3. Dependent Expression of MHC Class I. Related Chain A and B. Cancer Res., 2005, 65, 11136.
46. Schmudde, M.; Braun, A.; Pende, D.; Sonnemann, J.; Klier, U.; Beck, J. F.; Moretta, L.; Broker, B. M. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett., 2008, 272, 110-121.
47. Yamanegi, K.; Yamane, J.; Kobayashi, K.; Kato-Kogoe, N.; Ohyama, H.; Nakasho, K.; Yamada, N.; Hata, M.; Nishioka, T.; Fukunaga, S.; Futani, H.; Okamura, H.; Terada, N. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol. Rep., 2010, 24, 1621-1627.
48. Rohner, A.; Langenkamp, U.; Siegler, U.; Kalberer, C. P.; Wodnar-Filipowicz, A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res., 2007, 31, 1393-1402. (Pubitemid 47212430)
49. Bressan, A.; Bigioni, M.; Bellarosa, D.; Nardelli, F.; Irrissuto, C.; Maggi, C. A.; Binaschi, M. Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA. Oncol. Rep., 2010, 24, 1249-1255.
50. Poggi, A.; Catellani, S.; Garuti, A.; Pierri, I.; Gobbi, M.; Zocchi, M. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia, 2009, 23, 641-648.
51. Fine, J. H.; Chen, P.; Mesci, A.; Allan, D. S. J.; Gasser, S.; Raulet, D. H.; Carlyle, J. R. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res., 2010, 70, 7102.
52. Zhang, C.; Niu, J.; Zhang, J.; Wang, Y.; Zhou, Z.; Zhang, J.; Tian, Z. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Science, 2008, 99, 1279-1286. (Pubitemid 351676642)
53. Kohga, K.; Takehara, T.; Tatsumi, T.; Ishida, H.; Miyagi, T.; Hosui, A.; Hayashi, N. Sorafenib inhibits the shedding of major histocompatibility complex class I.related chain A on hepatocellular carcinoma cells by downregulating a disintegrin and metalloproteinase 9. Hepatology, 2010, 51, 1264-1273.
54. Kohga, K.; Takehara, T.; Tatsumi, T.; Miyagi, T.; Ishida, H.; Ohkawa, K.; Kanto, T.; Hiramatsu, N.; Hayashi, N. Anticancer Chemotherapy Inhibits MHC Class I. Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma. Cancer Res., 2009, 69, 8050.
55. Boissel, N.; Rea, D.; Tieng, V.; Dulphy, N.; Brun, M.; Cayuela, J. M.; Rousselot, P.; Tamouza, R.; Le Bouteiller, P.; Mahon, F. X.; Steinle, A.; Charron, D.; Dombret, H.; Toubert, A. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. The Journal of Immunology, 2006, 176, 5108.
56. Cebo, C.; Da Rocha, S.; Wittnebel, S.; Turhan, A. G.; Abdelali, J.; Caillat-Zucman, S.; Bourhis, J. H.; Chouaib, S.; Caignard, A. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. The Journal of Immunology, 2006, 176, 864.
57. Xu, X.; Rao, G.; Groh, V.; Spies, T.; Gattuso, P.; Kaufman, H.; Plate, J.; Prinz, R. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer, 2011, 11, 194.
58. Huang, Y.; Wang, Y.; Li, Y.; Guo, K.; He, Y. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG 2. J. Cancer Res. Clin. Oncol., 2010, 137, 829-837.
59. Seznec, J.; Silkenstedt, B.; Naumann, U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J. Neurooncol., 2011, 101, 365-77.
60. Salih, J.; Hilpert, J.; Placke, T.; Grunebach, F.; Steinle, A.; Salih, H. R.; Krusch, M. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. International Journal of cancer, 2010, 127, 2119-2128.
61. Bedel, R.; Thiery-Vuillemin, A.; Grandclement, C.; Balland, J.; Remy-Martin, J. P.; Kantelip, B.; Pallandre, J. R.; Pivot, X.; Ferrand, C.; Tiberghien, P.; Borg, C. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res., 2011, 71, 1615.
62. Riederer, I.; Sievert, W.; Eissner, G.; Molls, M.; Multhoff, G. Irradiation-Induced Up-Regulation of HLA-E on Macrovascular Endothelial Cells Confers Protection against Killing by Activated Natural Killer Cells. PLoS ONE, 2010, 5.
63. Creighton, C. J.; Li, X.; Landis, M.; Dixon, J. M.; Neumeister, V. M.; Sjolund, A.; Rimm, D. L.; Wong, H.; Rodriguez, A.; Herschkowitz, J. I.; Fan, C.; Zhang, X.; He, X.; Pavlick, A.; Gutierrez, M. C.; Renshaw, L.; Larionov, A. A.; Faratian, D.; Hilsenbeck, S. G.; Perou, C. M.; Lewis, M. T.; Rosen, J. M.; Chang, J. C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences, 2009, 106, 13820.
64. Latifi, A.; Abubaker, K.; Castrechini, N.; Ward, A. C.; Liongue, C.; Dobill, F.; Kumar, J.; Thompson, E. W.; Quinn, M. A.; Findlay, J. K.; Ahmed, N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell. Biochem., 2011, 112, 2850.
65. Tammali, R.; Saxena, A.; Srivastava, S. K.; Ramana, K. V. Aldose Reductase Inhibition Prevents Hypoxia-induced Increase in Hypoxiainducible Factor-1α (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) by Regulating 26 S Proteasome-mediated Protein Degradation in Human Colon Cancer Cells. Journal of Biological Chemistry, 2011, 286, 24089-24100.
66. Penuelas, S.; Noe, V.; Ciudad, C. J. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS Journal, 2005, 272, 696-710. (Pubitemid 40208873)
67. Li, Y.; Yang, X.; Su, L. J.; Flaig, T. W. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol. Rep., 2010, 24, 1019-1028.
68. * 1. Biochem. Biophys. Res. Commun., 1998, 247, 401-406. (Pubitemid 28420837)
69. Trog, D.; Yeghiazaryan, K.; Schild, H. H.; Golubnitschaja, O. Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment. Amino Acids, 2008, 34, 539-545.
70. Trog, D.; Fountoulakis, M.; Friedlein, A.; Golubnitschaja, O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics, 2006, 6, 2924-2930.
71. Major, O.; Szeifert, G. T.; Fazekas, I.; Vitanovics, D.; Csonka, E.; Kocsis, B.; Bori, Z.; Kemeny, A. A.; Nagy, Z. Effect of a single high-dose gamma irradiation on cultured cells in human cerebral arteriovenous malformation. Special Supplements, 2002, 97, 459-463. (Pubitemid 35424325)
72. Orosco, A.; Fromigue, O.; Bazille, C.; Entz-Werle, N.; Levillain, P.; Marie, P. J.; Modrowski, D. Syndecan-2 affects the basal and chemotherapyinduced apoptosis in osteosarcoma. Cancer Res., 2007, 67, 3708.
73. Oner-Iyidogan, Y.; Oner, P.; Kocak, H.; Lama, A.; Gurdol, F.; Bekpinar, S.; Unur, N.; Ozbek-Kir, Z. Evaluation of leukocyte arylsulphatase a, serum interleukin-6 and urinary heparan sulphate following tamoxifen therapy in breast cancer. Pharmacol. Res., 2005, 52, 340-345. (Pubitemid 41175995)
74. Zweegman, S.; Kessler, F. L.; Kerkhoven, R. M.; Heimerikx, M.; Celie, J. W. A. M.; Janssen, J. J. W. M.; Huijgens, P. C.; Drager, A. M.; van den Born, J. Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. Matrix Biology, 2007, 26, 561-571. (Pubitemid 47575879)
75. Nicolson, G. L.; Custead, S. E.; Dulski, K. M.; Milas, L. Effects of gamma irradiation on cultured rat and mouse microvessel endothelial cells: metastatic tumor cell adhesion, subendothelial matrix degradation, and secretion of tumor cell growth factors. Clinical and Experimental Metastasis, 1991, 9, 457-468.
76. Wegrowski, J.; Remy, J.; Martin, M.; Lafuma, C. Fibronectin and glycosaminoglycan synthesis by fibrotic pig fibroblasts in primary culture. Connect. Tissue Res., 1989, 23, 237-249.
77. * Physics, 1985, 11, 1629-1637. (Pubitemid 15233625)
78. Garrido, F.; Ruiz-Cabello, F.; Cabrera, T.; Perez-Villar, J. J.; Lopez-Botet, M.; Duggan-Keen, M.; Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 1997, 18, 89-95. (Pubitemid 27107103)
79. Tsuchikawa, T.; Yamamura, Y.; Shichinohe, T.; Hirano, S.; Kondo, S. The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2011, 1-7 (epub. ahead of print)
80. Wiltschke, C.; Krainer, M.; Wagner, A.; Linkesch, W.; Zielinski, C. C. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp. Hematol., 1995, 23, 402-406.
81. Prados, J.; Melguizo, C.; Fernandez, J.; Carrillo, E.; Marchal, J.; Boulaiz, H.; Martinez, A.; Rodriguez-Serrano, F.; Aranega, A. Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase. Neoplasma, 2006, 53, 226-231. (Pubitemid 43844381)
82. Bao, L.; Dunham, K.; Lucas, K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocytemediated tumor cell killing. Cancer Immunol. Immunother., 2011, 60, 1299-1307.
83. Fujita, K.; Tsujimura, A.; Miyagawa, Y.; Kiuchi, H.; Matsuoka, Y.; Takao, T.; Takada, S.; Nonomura, N.; Okuyama, A. Isolation of germ cells from leukemia and lymphoma cells in a human in vitro model: potential clinical application for restoring human fertility after anticancer therapy. Cancer Res., 2006, 66, 11166.
84. Lancillotti, F.; Giandomenico, V.; Affabris, E.; Fiorucci, G.; Romeo, G.; Rossi, G. B. Interferon α-2b and Retinoic Acid Combined Treatment Affects Proliferation and Gene Expression of Human Cervical Carcinoma Cells. Cancer Research, 1995, 55, 3158-3164.
85. Liu, W.; Fowler, D.; Smith, P.; Dalgleish, A. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer, 2009, 102, 115-123.
86. Samid, D.; Shack, S.; Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 1993, 91, 2288.
87. Ferrandina, G.; Melichar, B.; Loercher, A.; Verschraegen, C. F.; Kudelka, A. P.; Edwards, C. L.; Scambia, G.; Kavanagh, J. J.; Abbruzzese, J. L.; Freedman, R. S. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res., 1997, 57, 4309.
88. Ishioka, C.; Kanamaru, R.; Sato, T.; Dei, T.; Konishi, Y.; Asamura, M.; Wakui, A. Inhibitory effects of prostaglandin A2 on c-myc expression and cell cycle progression in human leukemia cell line HL-60. Cancer Res., 1988, 48, 2813.
89. Garnett, C. T.; Palena, C.; Chakarborty, M.; Tsang, K. Y.; Schlom, J.; Hodge, J. W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res., 2004, 64, 7985.
90. Reits, E. A.; Hodge, J. W.; Herberts, C. A.; Groothuis, T. A.; Chakraborty, M.; Wansley, E. K.; Camphausen, K.; Luiten, R. M.; de Ru, A. H.; Neijssen, J.; Griekspoor, A.; Mesman, E.; Verreck, F. A.; Spits, H.; Schlom, J.; van Veelen, P.; Neefjes, J. J. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med., 2006, 203, 1259.
91. Chiriva-Internati, M.; Grizzi, F.; Pinkston, J.; John Morrow, K.; D'Cunha, N.; Frezza, E. E.; Muzzio, P. C.; Martin Kast, W.; Cobos, E. Gammaradiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In vitro Cellular & Developmental Biology-Animal, 2006, 42, 89-95. (Pubitemid 44264512)
92. Klein, B.; Loven, D.; Lurie, H.; Rakowsky, E.; Nyska, A.; Levin, I.; Klein, T. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J. Neurosurg., 1994, 80, 1074-1077. (Pubitemid 24154185)
93. Davidson, B.; Elstrand, M. B.; McMaster, M. T.; Berner, A.; Kurman, R. J.; Risberg, B.; Trope, C. G.; Shih, I. M. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol., 2005, 96, 42-47. (Pubitemid 39612415)
94. Paul, P.; Rouas-Freiss, N.; Khalil-Daher, I.; Moreau, P.; Riteau, B.; Le Gal, F. A.; Avril, M. F.; Dausset, J.; Guillet, J. G.; Carosella, E. D. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proceedings of the National Academy of Sciences, 1998, 95, 4510.
95. Malmberg, K. J.; Levitsky, V.; Norell, H.; de Matos, C. T.; Carlsten, M.; Schedvins, K.; Rabbani, H.; Moretta, A.; Soderstrom, K.; Levitskaya, J.; Kiessling, R. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest., 2002, 110, 1515-1524.
96. Yie, S.; Yang, H.; Ye, S.; Li, K.; Dong, D.; Lin, X. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Annals of Surgical Oncology, 2007, 14, 2721-2729. (Pubitemid 47460633)
97. Polakova, K.; Bandzuchova, E.; Sabty, F.; Mistrik, M.; Demitrovicova, L.; Russ, G. Activation of HLA-G expression by 5-aza-2-deoxycytidine in malignant hematopoetic cells isolated from leukemia patients. Neoplasma, 2009, 56, 514-520.
98. Urosevic, M.; Kempf, W.; Zagrodnik, B.; Panizzon, R.; Burg, G.; Dummer, R. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin. Exp. Dermatol., 2005, 30, 422-425. (Pubitemid 40835346)
99. Levy, E. M.; Bianchini, M.; Von Euw, E. M.; Barrio, M. M.; Bravo, A. I.; Furman, D.; Domenichini, E.; Macagno, C.; Pinsky, V.; Zucchini, C. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol., 2008, 32, 633-641. (Pubitemid 351330470)
100. Brenner, B. G.; Friedman, G.; Margolese, R. G. The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer. Cancer, 1985, 56, 1543-1548. (Pubitemid 15228499)
101. Coca, S.; Perez-Piqueras, J.; Martinez, D.; Colmenarejo, A.; Saez, M. A.; Vallejo, C.; Martos, J. A.; Moreno, M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 1997, 79, 2320-2328. (Pubitemid 27251014)
102. Donskov, F.; von der Maase, H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. Journal of clinical oncology, 2006, 24, 1997.
103. Ishigami, S.; Natsugoe, S.; Tokuda, K.; Nakajo, A.; Che, X.; Iwashige, H.; Aridome, K.; Hokita, S.; Aikou, T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer, 2000, 88, 577-583. (Pubitemid 30056932)
104. Al Omar, S. Y.; Marshall, E.; Middleton, D.; Christmas, S. E. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology, 2011, 133, 94-104.
105. Epling-Burnette, P. K.; Bai, F.; Painter, J. S.; Rollison, D. E.; Salih, H. R.; Krusch, M.; Zou, J. X.; Ku, E.; Zhong, B.; Boulware, D.; Moscinski, L.; Wei, S.; Djeu, J. Y.; List, A. F. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood, 2007, 109, 4816.
106. Kiladjian, J.; Bourgeois, E.; Lobe, I.; Braun, T.; Visentin, G.; Bourhis, J.; Fenaux, P.; Chouaib, S.; Caignard, A. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia, 2006, 20, 463-470. (Pubitemid 43291745)
107. Verheyden, S.; Bernier, M.; Demanet, C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia, 2004, 18, 2002-2007. (Pubitemid 40028427)
108. Markasz, L.; Stuber, G.; Vanherberghen, B.; Flaberg, E.; Olah, E.; Carbone, E.; Eksborg, S.; Klein, E.; Skribek, H.; Szekely, L. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Molecular cancer therapeutics, 2007, 6, 644.
109. Wang, X.; Ottosson, A.; Ji, C.; Feng, X.; Nordenskjold, M.; Henter, J. I.; Fadeel, B.; Zheng, C. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica, 2009, 94, 470.
110. Schmiedel, B. J.; Arelin, V.; Gruenebach, F.; Krusch, M.; Schmidt, S. M.; Salih, H. R. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int. J. Cancer, 2011, 128, 2911-2922.
111. Ishikawa, K.; Shimoda, K.; Shiraishi, N.; Adachi, Y.; Kitano, S. Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer. Jpn. J. Clin. Oncol., 1998, 28, 374.
112. Garzetti, G. G.; Ciavattini, A.; Provinciali, M.; Valensise, H.; Romanini, C.; Fabris, N. Influence of neoadjuvant polychemotherapy on natural killer cell activity in patients with locally advanced cervical squamous carcinoma. Gynecol. Oncol., 1994, 52, 39-43. (Pubitemid 24066850)
113. Garzetti, G. G.; Ciavattini, A.; Muzzioli, M.; Romanini, C. Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation. Cancer, 1999, 85, 2226-2231. (Pubitemid 29215563)
114. Brenner, B. G.; Margolese, R. G. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. Cancer, 1991, 68, 482-488.
115. Rafique, M.; Adachi, W.; Koike, S.; Kajikawa, S.; Yazawa, K.; Sugenoya, A.; Amano, J. Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients. J. Surg. Oncol., 1997, 64, 324-330. (Pubitemid 27190824)
116. Katz, P.; Zaytoun, A.; Lee, J. Mechanisms of human cell-mediated cytotoxicity. III. Dependence of natural killing on microtubule and microfilament integrity. The Journal of Immunology, 1982, 129, 2816.
117. Chuang, L. T.; Lotzova, E.; Heath, J.; Cook, K. R.; Munkarah, A.; Morris, M.; Wharton, J. T. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res., 1994, 54, 1286.
118. Kubo, M.; Morisaki, T.; Matsumoto, K.; Tasaki, A.; Yamanaka, N.; Nakashima, H.; Kuroki, H.; Nakamura, K.; Nakamura, M.; Katano, M. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunology, Immunotherapy, 2005, 54, 468-476. (Pubitemid 40543686)
119. Sako, T.; Burioka, N.; Yasuda, K.; Tomita, K.; Miyata, M.; Kurai, J.; Chikumi, H.; Watanabe, M.; Suyama, H.; Fukuoka, Y.; Ueda, Y.; Shimizu, E. Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncol., 2004, 43, 15-19. (Pubitemid 38283168)
120. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer, 2002, 87, 21-27.
121. Lanier, L. L.; Ruitenberg, J.; Phillips, J. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. The Journal of Immunology, 1988, 141, 3478.
122. Perussia, B.; Trinchieri, G.; Jackson, A.; Warner, N. L.; Faust, J.; Rumpold, H.; Kraft, D.; Lanier, L. L. The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. The Journal of Immunology, 1984, 133, 180.
123. Kohrt, H. E.; Houot, R.; Goldstein, M. J.; Weiskopf, K.; Alizadeh, A. A.; Brody, J.; Müller, A.; Pachynski, R.; Czerwinski, D.; Coutre, S.; Chao, M. P.; Chen, L.; Tedder, T. F.; Levy, R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood, 2011, 117, 2423-2432.
124. Reynolds, C. W.; Reichardt, D.; Henkart, M.; Millard, P.; Henkart, P. Inhibition of NK and ADCC activity by antibodies against purified cytoplasmic granules from rat LGL tumors. J. Leukoc. Biol., 1987, 42, 642.
125. Quach, H.; Ritchie, D.; Stewart, A.; Neeson, P.; Harrison, S.; Smyth, M.; Prince, H. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2009, 24, 22-32.
126. Dauguet, N.; Fournié, J. J.; Poupot, R.; Poupot, M. Lenalidomide down regulates the production of interferon-[gamma] and the expression of inhibitory cytotoxic receptors of human Natural Killer cells. Cell. Immunol., 2010, 264, 163-170.
127. Hsu, A. K.; Quach, H.; Tai, T.; Prince, H. M.; Harrison, S. J.; Trapani, J. A.; Smyth, M. J.; Neeson, P.; Ritchie, D. S. The immunostimulatory effect of
128. Awan, F. T.; Lapalombella, R.; Trotta, R.; Butchar, J. P.; Yu, B.; Benson, D. M.; Roda, J. M.; Cheney, C.; Mo, X.; Lehman, A.; Jones, J.; Flynn, J.; Jarjoura, D.; Desjarlais, J. R.; Tridandapani, S.; Caligiuri, M. A.; Muthusamy, N.; Byrd, J. C. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood, 2010, 115, 1204.
129. Lapalombella, R.; Gowda, A.; Joshi, T.; Mehter, N.; Cheney, C.; Lehman, A.; Chen, C. S.; Johnson, A. J.; Caligiuri, M. A.; Tridandapani, S.; Muthusamy, N,; Byrd, J. C. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol., 2009, 144, 848-855.
130. Tai, Y. T.; Li, X. F.; Catley, L.; Coffey, R.; Breitkreutz, I.; Bae, J.; Song, W.; Podar, K.; Hideshima, T.; Chauhan, D.; Schlossman, R.; Richardson, P.; Treon, S. P.; Grewal, I. S.; Munshi, N. C.; Anderson, K. C. Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications. Cancer Res., 2005, 65, 11712.
131. Zhang, L.; Qian, Z.; Cai, Z.; Sun, L.; Wang, H.; Bartlett, J. B.; Yi, Q.; Wang, M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am. J. Hematol., 2009, 84, 553-559.
132. Reddy, N.; Hernandez-Ilizaliturri, F. J.; Deeb, G.; Roth, M.; Vaughn, M.; Knight, J.; Wallace, P.; Czuczman, M. S. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol., 2008, 140, 36-45. (Pubitemid 350233246)
133. Arnould, L.; Gelly, M.; Penault-Llorca, F.; Benoit, L.; Bonnetain, F.; Migeon, C.; Cabaret, V.; Fermeaux, V.; Bertheau, P.; Garnier, J.; Jeannin, J. F.; Coudert, B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer, 2006, 94, 259-267. (Pubitemid 43151545)
134. Takada, M.; Terunuma, H.; Deng, X.; Dewan, M. Z.; Saji, S.; Kuroi, K.; Yamamoto, N.; Toi, M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer, 2011, 18, 64-67.
135. McGinnes, K.; Florence, J.; Penny, R. The effect of radiotherapy on the natural killer (NK)-cell activity of cancer patients. J. Clin. Immunol., 1987, 7, 210-217. (Pubitemid 17095447)
136. Standish, L. J.; Torkelson, C.; Hamill, F. A.; Yim, D.; Hill-Force, A.; Fitzpatrick, A.; Olsen, M.; Schildt, S.; Sweet, E.; Wenner, C. A.; Martzen, M. R. Immune defects in breast cancer patients after radiotherapy. Journal of the Society for Integrative Oncology, 2008, 6, 110.
137. Mozaffari, F.; Lindemalm, C.; Choudhury, A.; Granstam-Björneklett, H.; Helander, I.; Lekander, M.; Mikaelsson, E.; Nilsson, B.; Ojutkangas, M. L.; Österborg, A.; Bergkvist, L.; Mellstedt, H. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo-and radiotherapy. Br. J. Cancer, 2007, 97, 105-111. (Pubitemid 47012095)
138. Mozaffari, F.; Lindemalm, C.; Choudhury, A.; Granstam-Björneklett, H.; Lekander, M.; Nilsson, B.; Ojutkangas, M. L.; Österborg, A.; Bergkvist, L.; Mellstedt, H. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunology, Immunotherapy, 2009, 58, 111-120.
139. Giebel, S.; Dziaczkowska, J.; Wojnar, J.; Krawczyk-Kulis, M.; Markiewicz, M.; Kruzel, T.; Wylezol, I.; Nowak, K.; Jagoda, K.; Holowiecki, J. The impact of immunosuppressive therapy on an early quantitative NK cell reconstitution after allogeneic haematopoietic cell transplantation. Ann. Transplant., 2005, 10, 29-33.
140. Vitale, C.; Chiossone, L.; Cantoni, C.; Morreale, G.; Cottalasso, F.; Moretti, S.; Pistorio, A.; Haupt, R.; Lanino, E.; Dini, G.; Moretta, L.; Mingari, M. C. The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur. J. Immunol., 2004, 34, 3028-3038. (Pubitemid 39549382)
141. Ruggeri, L.; Capanni, M.; Urbani, E.; Perruccio, K.; Shlomchik, W. D.; Tosti, A.; Posati, S.; Rogaia, D.; Frassoni, F.; Aversa, F.; Martelli, M. F.; Velardi, A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, 295, 2097.
142. Krusch, M.; Salih, J.; Schlicke, M.; Baessler, T.; Kampa, K. M.; Mayer, F.; Salih, H. R. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. The Journal of Immunology, 2009, 183, 8286.
143. Schmudde, M.; Friebe, E.; Sonnemann, J.; Beck, J. F.; Broker, B. M. Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett., 2010, 295, 173-181.
144. Watson, N. F. S.; Spendlove, I.; Madjd, Z.; McGilvray, R.; Green, A. R.; Ellis, I. O.; Scholefield, J. H.; Durrant, L. G. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. International journal of cancer, 2006, 118, 1445-1452.
145. Wagner, S. N.; Rebmann, V.; Willers, C. P.; Grosse-Wilde, H.; Goos, M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. The Lancet, 2000, 356, 220-221. (Pubitemid 30446980)
146. de Kruijf, E. M.; van Nes, J. G. H.; Sajet, A.; Tummers, Q. R. J. G.; Putter, H.; Osanto, S.; Speetjens, F. M.; Smit, V. T.; Liefers, G. J.; van de Velde, C. J. H.; Kuppen, P. J. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clinical Cancer Research, 2010, 16, 1272.
147. Vetter, C.; Lieb, W.; Bröcker, E.; Becker, J. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br. J. Cancer, 2004, 91, 1495-1499. (Pubitemid 39486354)
148. Kim, J. Y.; Son, Y. O.; Park, S. W.; Bae, J. H.; Chung, J. S.; Kim, H. H.; Chung, B. S.; Kim, S. H.; Kang, C. D. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med., 2006, 38, 474-484.
149. Bae, J. H.; Kim, J. Y.; Kim, M. J.; Chang, S. H.; Park, Y. S.; Son, C. H.; Park, S. J.; Chung, J. S.; Lee, E. Y.; Kim, S. H.; Kang, C. D. Quercetin enhances susceptibility to NK cell-mediated lysis of tumor cells through induction of NKG2D ligands and suppression of HSP70. Journal of Immunotherapy, 2010, 33, 391.
150. Shi, J.; Tricot, G. J.; Garg, T. K.; Malaviarachchi, P. A.; Szmania, S. M.; Kellum, R. E.; Storrie, B.; Mulder, A.; Shaughnessy, J. D.; Barlogie, B.; van Rhee, F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood, 2008, 111, 1309.